{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:28:21Z","timestamp":1775176101397,"version":"3.50.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T00:00:00Z","timestamp":1569283200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T00:00:00Z","timestamp":1569283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s00592-019-01426-2","type":"journal-article","created":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T20:02:31Z","timestamp":1569355351000},"page":"1247-1258","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The continuous challenge of antithrombotic strategies in diabetes: focus on direct oral anticoagulants"],"prefix":"10.1007","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0991-2615","authenticated-orcid":false,"given":"Fulvio","family":"Pomero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Dentali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Mumoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Salomone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavio","family":"Tangianu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovambattista","family":"Desideri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Mastroiacovo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,24]]},"reference":[{"issue":"1","key":"1426_CR1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/cd17-0119","volume":"36","author":"Standards of Medical Care in Diabetes","year":"2018","unstructured":"Standards of Medical Care in Diabetes (2018) Abridged for primary care providers. American Diabetes Association. Clin Diabetes 36(1):14\u201337","journal-title":"Clin Diabetes"},{"issue":"2","key":"1426_CR2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2337\/dc12-0783","volume":"36","author":"S Kodama","year":"2013","unstructured":"Kodama S, Tanaka S, Heianza Y et al (2013) Association between physical activity and risk of all-cause mortality and cardiovascular disease in patients with diabetes: a meta-analysis. Diabetes Care 36(2):471\u2013479","journal-title":"Diabetes Care"},{"issue":"3","key":"1426_CR3","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00592-018-1253-5","volume":"56","author":"LM Vetrone","year":"2019","unstructured":"Vetrone LM, Zaccardi F, Webb DR et al (2019) Cardiovascular and mortality events in type 2 diabetes cardiovascular outcomes trials: a systematic review with trend analysis. Acta Diabetol 56(3):331\u2013339","journal-title":"Acta Diabetol"},{"issue":"15","key":"1426_CR4","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","volume":"376","author":"A Rawshani","year":"2017","unstructured":"Rawshani A, Rawshani A, Franz\u00e9n S et al (2017) Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med 376(15):1407\u20131418","journal-title":"N Engl J Med"},{"issue":"1","key":"1426_CR5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12963-018-0166-4","volume":"16","author":"J Lin","year":"2018","unstructured":"Lin J, Thompson TJ, Cheng YJ et al (2018) Projection of the future diabetes burden in the United States through 2060. Popul Health Metr 16(1):9","journal-title":"Popul Health Metr"},{"key":"1426_CR6","unstructured":"http:\/\/www.cdc.gov\/diabetes\/statistics\/prevalence_national.htm . Accessed 20 Apr 2019"},{"issue":"2","key":"1426_CR7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00592-016-0899-0","volume":"54","author":"I Marzona","year":"2017","unstructured":"Marzona I, Avanzini F, Lucisano G et al (2017) Are all people with diabetes and cardiovascular risk factors or microvascular complications at very high risk? Findings from the Risk and Prevention Study. Acta Diabetol 54(2):123\u2013131","journal-title":"Acta Diabetol"},{"issue":"3","key":"1426_CR8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00592-017-1083-x","volume":"55","author":"A Ramezankhani","year":"2018","unstructured":"Ramezankhani A, Azizi F, Hadaegh F, Momenan AA (2018) Diabetes and number of years of life lost with and without cardiovascular disease: a multi-state homogeneous semi-Markov model. Acta Diabetol 55(3):253\u2013262","journal-title":"Acta Diabetol"},{"issue":"7","key":"1426_CR9","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1161\/CIRCULATIONAHA.109.913376","volume":"123","author":"JL Ferreiro","year":"2011","unstructured":"Ferreiro JL, Angiolillo DJ (2011) Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 123(7):798\u2013813","journal-title":"Circulation"},{"issue":"6","key":"1426_CR10","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00592-015-0746-8","volume":"52","author":"F Pomero","year":"2015","unstructured":"Pomero F, Di Minno MN, Fenoglio L, Gianni M, Ageno W, Dentali F (2015) Is diabetes a hypercoagulable state? A critical appraisal. Acta Diabetol 52(6):1007\u20131016","journal-title":"Acta Diabetol"},{"issue":"10","key":"1426_CR11","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1161\/CIRCULATIONAHA.114.014796","volume":"132","author":"MA Cavender","year":"2015","unstructured":"Cavender MA, Steg PG, Smith SC Jr, REACH Registry Investigators et al (2015) Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the reduction of atherothrombosis for continued health (REACH) registry. Circulation 132(10):923\u2013931","journal-title":"Circulation"},{"issue":"1","key":"1426_CR12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1055\/s-0038-1675816","volume":"119","author":"R De Caterina","year":"2019","unstructured":"De Caterina R, Ageno W, Agnelli G et al (2019) The non-vitamin K antagonist oral anticoagulants in heart disease: section V-special situations. Thromb Haemost 119(1):14\u201338","journal-title":"Thromb Haemost"},{"issue":"4","key":"1426_CR13","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.acvd.2015.01.009","volume":"108","author":"M Tadic","year":"2015","unstructured":"Tadic M, Cuspidi C (2015) Type 2 diabetes mellitus and atrial fibrillation: from mechanisms to clinical practice. Arch Cardiovasc Dis 108(4):269\u2013276","journal-title":"Arch Cardiovasc Dis"},{"key":"1426_CR14","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ijcard.2005.02.050","volume":"105","author":"MR Movahed","year":"2005","unstructured":"Movahed MR, Hashemzadeh M, Jamal MM (2005) Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol 105:315\u2013318","journal-title":"Int J Cardiol"},{"key":"1426_CR15","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0895-4356(01)00478-4","volume":"55","author":"A Ruigomez","year":"2002","unstructured":"Ruigomez A, Johansson S, Wallander MA, Rodriguez LA (2002) Incidence of chronic atrial fibrillation in general practice and its treatment pattern. J Clin Epidemiol 55:358\u2013363","journal-title":"J Clin Epidemiol"},{"key":"1426_CR16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-7-28","volume":"7","author":"OE Johansen","year":"2008","unstructured":"Johansen OE, Brustad E, Enger S, Tveit A (2008) Prevalence of abnormal glucose metabolism in atrial fibrillation: a case control study in 75-year old subjects. Cardiovasc Diabetol 7:28","journal-title":"Cardiovasc Diabetol"},{"key":"1426_CR17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.amjcard.2011.03.004","volume":"108","author":"RR Huxley","year":"2011","unstructured":"Huxley RR, Filion KB, Konety S et al (2011) Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol 108:56\u201362","journal-title":"Am J Cardiol"},{"key":"1426_CR18","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.amjcard.2014.07.045","volume":"114","author":"O Fatemi","year":"2014","unstructured":"Fatemi O, Yuriditsky E, Tsioufis C et al (2014) Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). Am J Cardiol 114:1217\u20131222","journal-title":"Am J Cardiol"},{"key":"1426_CR19","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1212\/01.wnl.0000267275.68538.8d","volume":"69","author":"Stroke Risk in Atrial Fibrillation Working Group","year":"2007","unstructured":"Stroke Risk in Atrial Fibrillation Working Group (2007) Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 69:546\u2013554","journal-title":"Neurology"},{"key":"1426_CR20","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jacc.2015.10.080","volume":"67","author":"JM Ashburner","year":"2016","unstructured":"Ashburner JM, Go AS, Chang Y et al (2016) Effect of diabetes and glycemic control on ischemic stroke risk in AF patients: ATRIA study. J Am Coll Cardiol 67:239\u2013247","journal-title":"J Am Coll Cardiol"},{"key":"1426_CR21","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jacc.2016.10.069","volume":"69","author":"G Patti","year":"2017","unstructured":"Patti G, Lucerna M, Cavallari I et al (2017) Insulin-requiring versus noninsulin-requiring diabetes and thromboembolic risk in patients with atrial fibrillation: PREFER in AF. J Am Coll Cardiol 69:409\u2013419","journal-title":"J Am Coll Cardiol"},{"key":"1426_CR22","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","volume":"285","author":"BF Gage","year":"2001","unstructured":"Gage BF, Waterman AD, Shannon W et al (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285:2864\u20132870","journal-title":"JAMA"},{"key":"1426_CR23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GY Lip","year":"2010","unstructured":"Lip GY, Nieuwlaat R, Pisters R et al (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137:263\u2013272","journal-title":"Chest"},{"key":"1426_CR24","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"BS KirchhofP","year":"2016","unstructured":"KirchhofP BS, Kotecha D et al (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:2893\u20132962","journal-title":"Eur Heart J"},{"key":"1426_CR25","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/1479164114525548","volume":"11","author":"L Ryden","year":"2014","unstructured":"Ryden L, Grant PJ, Anker SD, Berne C et al (2014) ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD\u2014summary. Diabetes Vasc Dis Res 11:133\u2013173","journal-title":"Diabetes Vasc Dis Res"},{"key":"1426_CR26","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","volume":"64","author":"CT January","year":"2014","unstructured":"January CT, Wann LS, Alpert JS et al (2014) 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64:e1\u2013e76","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"1426_CR27","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jacc.2014.11.046","volume":"65","author":"TF Chao","year":"2015","unstructured":"Chao TF, Liu CJ, Wang KL et al (2015) Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol 65(7):635\u2013642","journal-title":"J Am Coll Cardiol"},{"key":"1426_CR28","doi-asserted-by":"crossref","first-page":"d124","DOI":"10.1136\/bmj.d124","volume":"342","author":"JB Olesen","year":"2011","unstructured":"Olesen JB, Lip GY, Hansen ML et al (2011) Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 342:d124","journal-title":"BMJ"},{"issue":"4","key":"1426_CR29","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/jamacardio.2016.5224","volume":"2","author":"A Plitt","year":"2017","unstructured":"Plitt A, McGuire DK, Giugliano RP (2017) Atrial fibrillation, type 2 diabetes, and non-vitamin K antagonist oral anticoagulants: a review. JAMA Cardiol 2(4):442\u2013448","journal-title":"JAMA Cardiol"},{"key":"1426_CR30","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139\u20131151","journal-title":"N Engl J Med"},{"key":"1426_CR31","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981\u2013992","journal-title":"N Engl J Med"},{"key":"1426_CR32","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883\u2013891","journal-title":"N Engl J Med"},{"key":"1426_CR33","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093\u20132104","journal-title":"N Engl J Med"},{"issue":"4","key":"1426_CR34","doi-asserted-by":"crossref","first-page":"675.e8","DOI":"10.1016\/j.ahj.2015.07.006","volume":"170","author":"S Bansilal","year":"2015","unstructured":"Bansilal S, Bloomgarden Z, Halperin JL et al (2015) Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). Am Heart J 170(4):675.e8\u2013682.e8","journal-title":"Am Heart J"},{"key":"1426_CR35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijcard.2015.05.141","volume":"196","author":"M Brambatti","year":"2015","unstructured":"Brambatti M, Darius H, Oldgren J et al (2015) Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: results from the RE-LY trial. Int J Cardiol 196:127\u2013131","journal-title":"Int J Cardiol"},{"issue":"2","key":"1426_CR36","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/ehjcvp\/pvu024","volume":"1","author":"JA Ezekowitz","year":"2015","unstructured":"Ezekowitz JA, Lewis BS, Lopes RD et al (2015) Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. Eur Heart J Cardiovasc Pharmacother 1(2):86\u201394","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"8","key":"1426_CR37","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1161\/STROKEAHA.116.013540","volume":"47","author":"NS Rost","year":"2016","unstructured":"Rost NS, Giugliano RP, Ruff CT, ENGAGE AF-TIMI 48 Investigators et al (2016) Outcomes with edoxaban versus warfarin in patients with previous cerebrovascular events: findings from ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). Stroke 47(8):2075\u20132082","journal-title":"Stroke"},{"issue":"12","key":"1426_CR38","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S1474-4422(10)70274-X","volume":"9","author":"HC Diener","year":"2010","unstructured":"Diener HC, Connolly SJ, Ezekowitz MD, RE-LY study group et al (2010) Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 9(12):1157\u20131163","journal-title":"Lancet Neurol"},{"issue":"3","key":"1426_CR39","doi-asserted-by":"crossref","first-page":"e2876","DOI":"10.1002\/dmrr.2876","volume":"33","author":"G Patti","year":"2017","unstructured":"Patti G, Di Gioia G, Cavallari I, Nenna A (2017) Safety and efficacy of non-vitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: a study-level meta-analysis of phase III randomized trials. Diabetes Metab Res Rev 33(3):e2876","journal-title":"Diabetes Metab Res Rev"},{"issue":"7","key":"1426_CR40","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2459\/JCM.0000000000000524","volume":"18","author":"N Mumoli","year":"2017","unstructured":"Mumoli N, Mastroiacovo D, Tamborini-Permunian E et al (2017) Dabigatran in nonvalvular atrial fibrillation: from clinical trials to real-life experience. J Cardiovasc Med (Hagerstown) 18(7):467\u2013477","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"4","key":"1426_CR41","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","volume":"63","author":"P Reilly","year":"2014","unstructured":"Reilly P, Lehr T, Haertter S, RE-LY Investigators et al (2014) The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 63(4):321\u2013328","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"1426_CR42","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1016\/j.jacc.2014.02.549","volume":"63","author":"EM Hylek","year":"2014","unstructured":"Hylek EM, Held C, Alexander JH et al (2014) Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol 63(20):2141\u20132147","journal-title":"J Am Coll Cardiol"},{"issue":"suppl_1","key":"1426_CR43","first-page":"16551","volume":"134","author":"A Plitt","year":"2016","unstructured":"Plitt A, Ruff C, Goudev A et al (2016) Abstract 16551: efficacy and safety of oral anticoagulation in 21105 patients with atrial fibrillation stratified by diabetic status in the ENGAGE AF-TIMI 48 Trial. Circulation 134(suppl_1):16551","journal-title":"Circulation"},{"issue":"6","key":"1426_CR44","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00592-018-1133-z","volume":"55","author":"G Penno","year":"2018","unstructured":"Penno G, Solini A, Bonora E, Renal Insufficiency and Cardiovascular Events (RIACE) Study Group et al (2018) Defining the contribution of chronic kidney disease to all-cause mortality in patients with type 2 diabetes: the renal insufficiency and cardiovascular events (RIACE) Italian Multicenter Study. Acta Diabetol 55(6):603\u2013612","journal-title":"Acta Diabetol"},{"issue":"1","key":"1426_CR45","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12933-019-0818-0","volume":"18","author":"SI Yamagishi","year":"2019","unstructured":"Yamagishi SI (2019) Concerns about clinical efficacy and safety of warfarin in diabetic patients with atrial fibrillation. Cardiovasc Diabetol 18(1):12","journal-title":"Cardiovasc Diabetol"},{"issue":"21","key":"1426_CR46","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.jacc.2016.09.926","volume":"68","author":"SV Brodsky","year":"2016","unstructured":"Brodsky SV, Hebert L (2016) Anticoagulant-related nephropathy: an AKI elephant hiding in plain view? J Am Coll Cardiol 68(21):2284\u20132286","journal-title":"J Am Coll Cardiol"},{"key":"1426_CR47","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijcard.2018.02.075","volume":"265","author":"Y-H Chan","year":"2018","unstructured":"Chan Y-H, Yeh Y-H, Hsieh MY et al (2018) The risk of acute kidney injury in Asians treated with apixaban, rivaroxaban, dabigatran, or warfarin for non-valvular atrial fibrillation: a nationwide cohort study in Taiwan. Int J Cardiol 265:83\u201389","journal-title":"Int J Cardiol"},{"key":"1426_CR48","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3389\/fphar.2018.00348","volume":"9","author":"ZC Gu","year":"2018","unstructured":"Gu ZC, Zhou LY, Shen L et al (2018) Non-vitamin K antagonist oral anticoagulants vs. warfarin at risk of fractures: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol 9:348","journal-title":"Front Pharmacol"},{"issue":"2","key":"1426_CR49","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41569-018-0080-2","volume":"16","author":"G Patti","year":"2019","unstructured":"Patti G, Cavallari I, Andreotti F, Working Group on Thrombosis of the Italian Society of Cardiology et al (2019) Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. Nat Rev Cardiol 16(2):113\u2013130","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"1426_CR50","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/europace\/euy174","volume":"21","author":"GYH Lip","year":"2019","unstructured":"Lip GYH, Collet JP, Haude M, ESC Scientific Document Group et al (2019) Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace 21(2):192\u2013193","journal-title":"Europace"},{"key":"1426_CR51","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","volume":"375","author":"CM Gibson","year":"2016","unstructured":"Gibson CM, Mehran R, Bode C et al (2016) Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 375:2423\u20132434","journal-title":"N Engl J Med"},{"key":"1426_CR52","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","volume":"377","author":"CP Cannon","year":"2017","unstructured":"Cannon CP, Bhatt DL, Oldgren J et al (2017) Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 377:1513\u20131524","journal-title":"N Engl J Med"},{"key":"1426_CR53","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","volume":"380","author":"RD Lopes","year":"2019","unstructured":"Lopes RD, Heizer G, Aronson R et al (2019) Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 380:1509\u20131524","journal-title":"N Engl J Med"},{"key":"1426_CR54","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ahj.2017.10.009","volume":"196","author":"P Vranckx","year":"2018","unstructured":"Vranckx P, Lewalter T, Valgimigli M et al (2018) Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: rationale and design of the ENTRUST-AF PCI trial. Am Heart J 196:105\u2013112","journal-title":"Am Heart J"},{"issue":"1","key":"1426_CR55","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/eurheartj\/ehp504","volume":"31","author":"DJ Angiolillo","year":"2010","unstructured":"Angiolillo DJ, Capodanno D, Goto S (2010) Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J 31(1):17\u201328","journal-title":"Eur Heart J"},{"issue":"14","key":"1426_CR56","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","volume":"377","author":"JW Eikelboom","year":"2017","unstructured":"Eikelboom JW, Connolly SJ, Bosch J et al (2017) Rivaroxaban with or without Aspirin in stable cardiovascular disease. N Engl J Med 377(14):1319\u20131330","journal-title":"N Engl J Med"},{"issue":"9","key":"1426_CR57","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1161\/CIRCULATIONAHA.118.035864","volume":"139","author":"M Sharma","year":"2019","unstructured":"Sharma M, Hart RG, Connolly SJ et al (2019) Stroke outcomes in the COMPASS trial. Circulation 139(9):1134\u20131145","journal-title":"Circulation"},{"issue":"10117","key":"1426_CR58","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0140-6736(17)32458-3","volume":"391","author":"SJ Connolly","year":"2018","unstructured":"Connolly SJ, Eikelboom JW, Bosch J, COMPASS investigators et al (2018) Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 391(10117):205\u2013218","journal-title":"Lancet"},{"issue":"10117","key":"1426_CR59","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","volume":"391","author":"SS Anand","year":"2018","unstructured":"Anand SS, Bosch J, Eikelboom JW, COMPASS Investigators et al (2018) Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 391(10117):219\u2013229","journal-title":"Lancet"},{"key":"1426_CR60","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ahj.2018.01.011","volume":"199","author":"WH Capell","year":"2018","unstructured":"Capell WH, Bonaca MP, Nehler MR et al (2018) Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). Am Heart J 199:83\u201391","journal-title":"Am Heart J"},{"issue":"2","key":"1426_CR61","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jamacardio.2018.4537","volume":"4","author":"J Gregson","year":"2019","unstructured":"Gregson J, Kaptoge S, Bolton T et al (2019) Emerging risk factors collaboration. cardiovascular risk factors associated with venous thromboembolism. JAMA Cardiol 4(2):163\u2013173","journal-title":"JAMA Cardiol"},{"issue":"12","key":"1426_CR62","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1136\/heartjnl-2014-307019","volume":"102","author":"AD Blann","year":"2016","unstructured":"Blann AD, Lip GY (2016) Non-vitamin K antagonist oral anticoagulants (NOACs) for the management of venous thromboembolism. Heart 102(12):975\u2013983","journal-title":"Heart"},{"issue":"3","key":"1426_CR63","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s11739-017-1628-6","volume":"12","author":"D Prisco","year":"2017","unstructured":"Prisco D, Ageno W, Becattini C, SIMI (Italian Society of Internal Medicine); FADOI (Federation of Associations of Hospital Doctors on Internal Medicine); SISET (Italian Society for the Study of Haemostasis and Thrombosis) et al (2017) Italian intersociety consensus on DOAC use in internal medicine. Intern Emerg Med 12(3):387\u2013406","journal-title":"Intern Emerg Med"},{"issue":"16","key":"1426_CR64","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","volume":"39","author":"J Steffel","year":"2018","unstructured":"Steffel J, Verhamme P, Potpara TS, ESC Scientific Document Group et al (2018) The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39(16):1330\u20131393","journal-title":"Eur Heart J"},{"issue":"25","key":"1426_CR65","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1016\/j.jacc.2013.02.058","volume":"61","author":"JD Wessler","year":"2013","unstructured":"Wessler JD, Grip LT, Mendell J, Giugliano RP (2013) The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol 61(25):2495\u20132502","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1426_CR66","first-page":"177","volume":"11","author":"MM Abbasi","year":"2016","unstructured":"Abbasi MM, Valizadeh H, Hamishehkar H, Zakeri-Milani P (2016) Inhibition of P-glycoprotein expression and function by anti-diabetic drugs gliclazide, metformin, and pioglitazone in vitro and in situ. Res Pharm Sci 11(3):177\u2013186","journal-title":"Res Pharm Sci"},{"issue":"9","key":"1426_CR67","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1517\/17425255.2011.586337","volume":"7","author":"AJ Scheen","year":"2011","unstructured":"Scheen AJ (2011) Cytochrome P450-mediated cardiovascular drug interactions. Expert Opin Drug Metab Toxicol 7(9):1065\u20131082","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1426_CR68","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.phrs.2016.11.005","volume":"115","author":"M Ruscica","year":"2017","unstructured":"Ruscica M, Baldessin L, Boccia D, Racagni G, Mitro N (2017) Non-insulin anti-diabetic drugs: an update on pharmacological interactions. Pharmacol Res 115:14\u201324","journal-title":"Pharmacol Res"},{"key":"1426_CR69","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.phrs.2018.07.016","volume":"135","author":"P Gelosa","year":"2018","unstructured":"Gelosa P, Castiglioni L, Tenconi M et al (2018) Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs). Pharmacol Res 135:60\u201379","journal-title":"Pharmacol Res"},{"key":"1426_CR70","unstructured":"www.ema.europa.eu\/en\/documents\/product-information . Accessed 13 May 2019"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-019-01426-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00592-019-01426-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-019-01426-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T02:22:45Z","timestamp":1611368565000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00592-019-01426-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,24]]},"references-count":70,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1426"],"URL":"https:\/\/doi.org\/10.1007\/s00592-019-01426-2","relation":{},"ISSN":["0940-5429","1432-5233"],"issn-type":[{"value":"0940-5429","type":"print"},{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,24]]},"assertion":[{"value":"3 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human partecipants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard"}},{"value":"For this type of study formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}